Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 2, 2011, Pages 223-235

  Marathe, Anshu ^a   Van Wart, Scott ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Interferon ; NONMEM; Pharmacokinetics; Rapid binding approximation; Simulation; Target mediated drug disposition

Indexed keywords

RECOMBINANT BETA INTERFERON;

ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG RECEPTOR BINDING; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; RECEPTOR DENSITY; SYSTEMATIC ERROR; TARGET MEDIATED DRUG DISPOSITION MODEL;

COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; INTERFERON-BETA; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING;

EID: 79956014415     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-010-9190-0     Document Type: Article

References (14)

1. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252
2. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10
3. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532 (Pubitemid 34289541)
4. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35: 573-591
5. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596 (Pubitemid 41355898)
6. Dutta S, Matsumoto Y, Ebling WF (1996) Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 85:232-239
7. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR (2003) Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 307:969-976 (Pubitemid 37494214)
8. Abraham AK, Krzyzanski W, Mager DE (2007) Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J 9:E181-E189
9. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306:262-270 (Pubitemid 36734381)
10. Beal SL, Sheiner LB (1989-1998) NONMEM users guides. Icon Development Solutions, Ellicott City, MD
11. Bonate P (2006) Nonlinear mixed effects models: theory, chap 7. In: Pharmacokinetic-pharmacodynamic modeling and simulation. Springer, New York, pp 205-265
12. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
13. Mager DE, Woo S, Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16-24
14. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man. Pharm Res 24:2031-2039 (Pubitemid 47493572)